Health and Healthcare

Alexion Pharmaceuticals, Inc. : ALXN

All ALXN Articles

307 Articles

Chris Lange | Oct 27, 2015 at 8:10 AM EDT

Short Sellers Become More Selective on Leading Biotechs

The October 15 short interest data have been compared with the previous figures, and short interest mixed in these selected…

Lee Jackson | Oct 20, 2015 at 10:05 AM EDT

Q3 Worst for Biotech in 7 Years: Which Large Cap Leaders to Buy Now

Cowen says the way to play biotech is with large cap sector leaders that can beat earnings estimates. It also…

Chris Lange | Oct 12, 2015 at 8:20 AM EDT

Short Sellers Increase Bets in Major Biotechs

The September 30 short interest data have been compared with the previous figures, and short interest increased in most of…

Lee Jackson | Oct 7, 2015 at 8:40 AM EDT

Why Merrill Lynch Now Favors Large Cap Leaders in Biotech

These four top large cap biotechs are very good bets for investors looking to add high-quality companies with less volatility…

Chris Lange | Sep 26, 2015 at 9:25 AM EDT

How the Top Biotechs Handled the Valuation Shock

24/7 Wall St. has taken a look at some of the largest biotech companies and highlighted the damage that a…

Chris Lange | Sep 25, 2015 at 8:05 AM EDT

Short Sellers Increase Bets in Major Biotech

The September 15 short interest data have been compared with the previous figures, and short interest in these selected stocks…

Chris Lange | Sep 24, 2015 at 9:55 AM EDT

Why Oppenheimer Says Alexion Is a Cheap Buy Now

Oppenheimer maintained its Outperform rating for Alexion Pharmaceuticals with a price target that implies upside of more than 40%.

Jon C. Ogg | Sep 14, 2015 at 8:55 AM EDT

Top Analyst Upgrades and Downgrades: AeroVironment, Gold Fields, Marvell, Nokia, Silver Wheaton and Many More

Monday's top analyst upgrades, downgrades and initiations include AeroVironment, Gold Fields, Marvell Technology, Nokia and Silver Wheaton.

Chris Lange | Sep 11, 2015 at 8:05 AM EDT

Short Sellers Increase Bets in Major Biotechs

The short interest data are out for the August 31 settlement date. Short interest in the selected biotech stocks increased…

Chris Lange | Aug 26, 2015 at 8:55 AM EDT

Short Sellers Become More Focused in Major Biotechs

The short interest data are out for the August 14 settlement date. Biotech companies are considered a riskier group of…

Lee Jackson | Aug 13, 2015 at 9:20 AM EDT

JPMorgan Has Favorite Biotech Stocks to Buy for Rest of 2015

In a new research report, JPMorgan highlights its favorite biotech stocks to buy after the second-quarter earnings print.

Chris Lange | Aug 12, 2015 at 8:55 AM EDT

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the July 31 settlement date, and overall, short interest in the selected biotech…

Lee Jackson | Aug 10, 2015 at 8:20 AM EDT

3 Large Biotech Stocks to Buy Despite Higher Interest Rates Coming

Merrill Lynch has looked at large cap biotech leaders and how interest rate increases may play a part in stock…

Lee Jackson | Aug 4, 2015 at 8:35 AM EDT

3 Potential Huge Takeover Targets in Biotech

In a new research report, Cowen's well-respected analyst Ken Cacciatore makes a very good case that some huge, high-profile biotech…

Chris Lange | Jul 27, 2015 at 7:57 AM EDT

Short Sellers Back Off Major Biotechs

ThinkstockThe short interest data are out for the July 15 settlement date. Biotech companies are considered a riskier group of…

1 … 13 14 15 16 17 … 21

Alexion Pharmaceuticals, Inc. : ALXN

All ALXN Articles

Short Sellers Become More Selective on Leading Biotechs

Q3 Worst for Biotech in 7 Years: Which Large Cap Leaders to Buy Now

Short Sellers Increase Bets in Major Biotechs

Why Merrill Lynch Now Favors Large Cap Leaders in Biotech

How the Top Biotechs Handled the Valuation Shock

Short Sellers Increase Bets in Major Biotech

Why Oppenheimer Says Alexion Is a Cheap Buy Now

Top Analyst Upgrades and Downgrades: AeroVironment, Gold Fields, Marvell, Nokia, Silver Wheaton and Many More

Short Sellers Increase Bets in Major Biotechs

Short Sellers Become More Focused in Major Biotechs

JPMorgan Has Favorite Biotech Stocks to Buy for Rest of 2015

Short Sellers Run for Cover From Major Biotechs

3 Large Biotech Stocks to Buy Despite Higher Interest Rates Coming

3 Potential Huge Takeover Targets in Biotech

Short Sellers Back Off Major Biotechs

MISL Investors: Watch the FY27 Budget Bill Before the Next Rally

Fed’s Rate Freeze Could Sting for Social Security Recipients

‘Convert $100,000 a Year to Get Them to the Top of the 22%’: The Roth Plan for a Couple With $2.3M in 401(k)s

Fed’s Rate Freeze Could Sting for Social Security Recipients

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s

MISL Investors: Watch the FY27 Budget Bill Before the Next Rally

Fed’s Rate Freeze Could Sting for Social Security Recipients

Alexion Pharmaceuticals, Inc. : ALXN

All ALXN Articles

Short Sellers Become More Selective on Leading Biotechs

Q3 Worst for Biotech in 7 Years: Which Large Cap Leaders to Buy Now

Short Sellers Increase Bets in Major Biotechs

Why Merrill Lynch Now Favors Large Cap Leaders in Biotech

How the Top Biotechs Handled the Valuation Shock

Short Sellers Increase Bets in Major Biotech

Why Oppenheimer Says Alexion Is a Cheap Buy Now

Top Analyst Upgrades and Downgrades: AeroVironment, Gold Fields, Marvell, Nokia, Silver Wheaton and Many More

Short Sellers Increase Bets in Major Biotechs

Short Sellers Become More Focused in Major Biotechs

JPMorgan Has Favorite Biotech Stocks to Buy for Rest of 2015

Short Sellers Run for Cover From Major Biotechs

3 Large Biotech Stocks to Buy Despite Higher Interest Rates Coming

3 Potential Huge Takeover Targets in Biotech

Short Sellers Back Off Major Biotechs

MISL Investors: Watch the FY27 Budget Bill Before the Next Rally

Fed’s Rate Freeze Could Sting for Social Security Recipients

‘Convert $100,000 a Year to Get Them to the Top of the 22%’: The Roth Plan for a Couple With $2.3M in 401(k)s

Featured Reads

Fed’s Rate Freeze Could Sting for Social Security Recipients

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s